Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebo-controlled, randomised, double blind, multi-centre study
Traumatic brain injury is a leading cause of death and disability worldwide. The nitric oxide synthase inhibitor Ronopterin was shown to improve clinical outcome by enhancing neuroprotection in a phase IIa trial.
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
14 January 2020
|
| In: |
Trials
Year: 2020, Volume: 21, Pages: 1-9 |
| ISSN: | 1468-6694 |
| DOI: | 10.1186/s13063-019-3965-4 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s13063-019-3965-4
|
| Author Notes: | Frank Tegtmeier, Reinhard Schinzel, Ronny Beer, Diederik Bulters, Jean-Yves LeFrant, Joan Sahuquillo, Andreas Unterberg, Peter Andrews, Antonio Belli, Javier Ibanez, Alfonso Lagares, Michael Mokry, Harald Willschke, Charlotte Flüh, Erich Schmutzhard and on behalf of the NOSTRA Investigators |
| Summary: | Traumatic brain injury is a leading cause of death and disability worldwide. The nitric oxide synthase inhibitor Ronopterin was shown to improve clinical outcome by enhancing neuroprotection in a phase IIa trial. |
|---|---|
| Item Description: | Gesehen am 02.04.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1468-6694 |
| DOI: | 10.1186/s13063-019-3965-4 |